HIF Activation Against CVD in CKD: Novel Treatment Opportunities

Seminars in Nephrology

Volumn 38, Issue 3, 2018, Pages 267-276

  Tanaka, Tetsuhiro ^a   Eckardt, Kai Uwe ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CKD; CVD; HIF; PHD inhibitor

Indexed keywords

ANTIANEMIC AGENT; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; INSULIN INDUCED GENE 2 PROTEIN; MEMBRANE PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; FIBROBLAST GROWTH FACTOR; HIF3A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA;

ADAPTATION; ADVERSE OUTCOME; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; ENZYME INHIBITION; GENE; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE REMODELING; HIF2A GENE; HUMAN; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHD2 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECT; GENETICS;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; ATHEROSCLEROSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOOD PRESSURE; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MYOCARDIAL INFARCTION; PROLYL HYDROXYLASES; PROLYL-HYDROXYLASE INHIBITORS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85046665675     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2018.02.006     Document Type: Review

References (83)

1. Go, A.S., Chertow, G.M., Fan, D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
2. Keith, D.S., Nichols, G.A., Gullion, C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004), 659–663.
3. Silverberg, D., Wexler, D., Blum, M., et al. The cardio-renal anaemia syndrome: does it exist?. Nephrol Dial Transplant 18:Suppl 8 (2003), viii7–viii12.
4. Maxwell, P.H., Eckardt, K.U., HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 12 (2016), 157–168.
5. Hu, C.J., Wang, L.Y., Chodosh, L.A., et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23 (2003), 9361–9374.
6. Berra, E., Benizri, E., Ginouves, A., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22 (2003), 4082–4090.
7. Appelhoff, R.J., Tian, Y.M., Raval, R.R., et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279 (2004), 38458–38465.
8. Warnecke, C., Zaborowska, Z., Kurreck, J., et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18 (2004), 1462–1464.
9. Kojima, I., Tanaka, T., Inagi, R., et al. Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol 18 (2007), 1218–1226.
10. Minamishima, Y.A., Moslehi, J., Bardeesy, N., et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111 (2008), 3236–3244.
11. Percy, M.J., Furlow, P.W., Lucas, G.S., et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358 (2008), 162–168.
12. Percy, M.J., Zhao, Q., Flores, A., et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 103 (2006), 654–659.
13. Sugahara, M., Tanaka, T., Nangaku, M., Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int 92 (2017), 306–312.
14. McCullough, P.A., Barnhart, H.X., Inrig, J.K., et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 37 (2013), 549–558.
15. Drueke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006), 2071–2084.
16. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
17. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
18. KDIGO Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int Suppl 2 (2012), 279–335.
19. Kido, M., Du, L., Sullivan, C.C., et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 46 (2005), 2116–2124.
20. Eckle, T., Kohler, D., Lehmann, R., et al. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118 (2008), 166–175.
21. Holscher, M., Silter, M., Krull, S., et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem 286 (2011), 11185–11194.
22. Hyvarinen, J., Hassinen, I.E., Sormunen, R., et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 285 (2010), 13646–13657.
23. Vogler, M., Zieseniss, A., Hesse, A.R., et al. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch 467 (2015), 2141–2149.
24. Moslehi, J., Minamishima, Y.A., Shi, J., et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122 (2010), 1004–1016.
25. Lei, L., Mason, S., Liu, D., et al. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol 28 (2008), 3790–3803.
26. Krishnan, J., Suter, M., Windak, R., et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 9 (2009), 512–524.
27. Sano, M., Minamino, T., Toko, H., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446 (2007), 444–448.
28. Wei, H., Bedja, D., Koitabashi, N., et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-beta signaling. Proc Natl Acad Sci U S A 109 (2012), E841–E850.
29. Levine, B., Kalman, J., Mayer, L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990), 236–241.
30. Rauchhaus, M., Doehner, W., Francis, D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000), 3060–3067.
31. Nahrendorf, M., Swirski, F.K., Aikawa, E., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204 (2007), 3037–3047.
32. Melillo, G., Musso, T., Sica, A., et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182 (1995), 1683–1693.
33. Semba, H., Takeda, N., Isagawa, T., et al. HIF-1alpha-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity. Nat Commun, 7, 2016, 11635.
34. Cramer, T., Yamanishi, Y., Clausen, B.E., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003), 645–657.
35. Sadiku, P., Willson, J.A., Dickinson, R.S., et al. Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. J Clin Invest 127 (2017), 3407–3420.
36. Isakova, T., Xie, H., Yang, W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
37. Grabner, A., Mazzaferro, S., Cianciolo, G., et al. Fibroblast growth factor 23: mineral metabolism and beyond. Contrib Nephrol 190 (2017), 83–95.
38. Faul, C., Amaral, A.P., Oskouei, B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (2011), 4393–4408.
39. Grabner, A., Amaral, A.P., Schramm, K., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22 (2015), 1020–1032.
40. David, V., Martin, A., Isakova, T., et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 (2016), 135–146.
41. Flamme, I., Ellinghaus, P., Urrego, D., et al. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One, 12, 2017, e0186979.
42. Honda, H., Michihata, T., Shishido, K., et al. High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients. PLoS One, 12, 2017, e0176984.
43. Arias-Stella, J., Saldana, M., The terminal portion of the pulmonary arterial tree in people native to high altitudes. Circulation 28 (1963), 915–925.
44. Gale, D.P., Harten, S.K., Reid, C.D., et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 112 (2008), 919–921.
45. Talbot, N.P., Smith, T.G., Balanos, G.M., et al. Cardiopulmonary phenotype associated with human PHD2 mutation. Physiol Rep, 5, 2017, 7.
46. Smith, T.G., Brooks, J.T., Balanos, G.M., et al. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med, 3, 2006, e290.
47. Lorenzo, F.R., Huff, C., Myllymaki, M., et al. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet 46 (2014), 951–956.
48. Petousi, N., Croft, Q.P., Cavalleri, G.L., et al. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia. J Appl Physiol 116 (1985), 893–904.
49. Brusselmans, K., Compernolle, V., Tjwa, M., et al. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 111 (2003), 1519–1527.
50. Cowburn, A.S., Crosby, A., Macias, D., et al. HIF2alpha-arginase axis is essential for the development of pulmonary hypertension. Proc Natl Acad Sci U S A 113 (2016), 8801–8806.
51. Tan, Q., Kerestes, H., Percy, M.J., et al. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem 288 (2013), 17134–17144.
52. Bolignano, D., Rastelli, S., Agarwal, R., et al. Pulmonary hypertension in CKD. Am J Kidney Dis 61 (2013), 612–622.
53. Eltzschig, H.K., Carmeliet, P., Hypoxia and inflammation. N Engl J Med 364 (2011), 656–665.
54. Sluimer, J.C., Gasc, J.M., van Wanroij, J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 51 (2008), 1258–1265.
55. Chaudhari, S.M., Sluimer, J.C., Koch, M., et al. Deficiency of HIF1alpha in antigen-presenting cells aggravates atherosclerosis and type 1 T-helper cell responses in mice. Arterioscler Thromb Vasc Biol 35 (2015), 2316–2325.
56. Aarup, A., Pedersen, T.X., Junker, N., et al. Hypoxia-inducible factor-1alpha expression in macrophages promotes development of atherosclerosis. Arterioscler Thromb Vasc Biol 36 (2016), 1782–1790.
57. Yoshida, H., Kondratenko, N., Green, S., et al. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 334 (1998), 9–13.
58. Crucet, M., Wust, S.J., Spielmann, P., et al. Hypoxia enhances lipid uptake in macrophages: role of the scavenger receptors Lox1, SRA, and CD36. Atherosclerosis 229 (2013), 110–117.
59. Chen, M., Masaki, T., Sawamura, T., LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95 (2002), 89–100.
60. Choi, J.H., Kim, K.L., Huh, W., et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 (2004), 1246–1252.
61. Di Marco, G.S., Reuter, S., Hillebrand, U., et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20 (2009), 2235–2245.
62. Schellinger, I.N., Cordasic, N., Panesar, J., et al. Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease. Kidney Int 91 (2017), 616–627.
63. Provenzano, R., Besarab, A., Sun, C.H., et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 11 (2016), 982–991.
64. Provenzano, R., Besarab, A., Wright, S., et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67 (2016), 912–924.
65. Akizawa, T., Tsubakihara, Y., Nangaku, M., et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol 45 (2017), 127–135.
66. Martin, E.R., Smith, M.T., Maroni, B.J., et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol 45 (2017), 380–388.
67. Rahtu-Korpela, L., Karsikas, S., Horkko, S., et al. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes 63 (2014), 3324–3333.
68. Matsuura, H., Ichiki, T., Inoue, E., et al. Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance. Circulation 127 (2013), 2078–2087.
69. Hwang, S., Nguyen, A.D., Jo, Y., et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem 292 (2017), 9382–9393.
70. Marsch, E., Demandt, J.A., Theelen, T.L., et al. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur Heart J 37 (2016), 2993–2997.
71. Besarab, A., Chernyavskaya, E., Motylev, I., et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27 (2016), 1225–1233.
72. Pergola, P.E., Spinowitz, B.S., Hartman, C.S., et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90 (2016), 1115–1122.
73. Locatelli, F., Olivares, J., Walker, R., et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60 (2001), 741–747.
74. Flamme, I., Oehme, F., Ellinghaus, P., et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One, 9, 2014, e111838.
75. Cowburn, A.S., Takeda, N., Boutin, A.T., et al. HIF isoforms in the skin differentially regulate systemic arterial pressure. Proc Natl Acad Sci U S A 110 (2013), 17570–17575.
76. Takeda, N., O'Dea, E.L., Doedens, A., et al. Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev 24 (2010), 491–501.
77. Bishop, T., Gallagher, D., Pascual, A., et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol 28 (2008), 3386–3400.
78. Peng, Y.J., Nanduri, J., Khan, S.A., et al. Hypoxia-inducible factor 2alpha (HIF-2alpha) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension. Proc Natl Acad Sci U S A 108 (2011), 3065–3070.
79. Wang, Z., Zhu, Q., Xia, M., et al. Hypoxia-inducible factor prolyl-hydroxylase 2 senses high-salt intake to increase hypoxia inducible factor 1alpha levels in the renal medulla. Hypertension 55 (2010), 1129–1136.
80. Zhu, Q., Wang, Z., Xia, M., et al. Overexpression of HIF-1alpha transgene in the renal medulla attenuated salt sensitive hypertension in Dahl S rats. Biochim Biophys Acta 1822 (2012), 936–941.
81. Zhu, Q., Hu, J., Han, W.Q., et al. Silencing of HIF prolyl-hydroxylase 2 gene in the renal medulla attenuates salt-sensitive hypertension in Dahl S rats. Am J Hypertens 27 (2014), 107–113.
82. Yamanaka, S., Yokote, S., Yamada, A., et al. Correction: adipose tissue-derived mesenchymal stem cells in long-term dialysis patients display downregulation of PCAF expression and poor angiogenesis activation. PLoS One, 11, 2016, e0157282.
83. Yamaguchi, J., Tanaka, T., Eto, N., et al. Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein delta. Kidney Int 88 (2015), 262–275.